Parkinsonism & Related Disorders

Article	Citations
Altered glymphatic system in idiopathic normal pressure hydrocephalus	99
Linear predictive coding distinguishes spectral EEG features of Parkinson's disease	72
Predictors of COVID-19 outcome in Parkinson's disease	63
Diffusion along perivascular spaces reveals evidence supportive of glymphatic function impairment in Parkinson disease	63
Increased microglial activation in patients with Parkinson disease using [18F]-DPA714 TSPO PET imaging	62
Altered gut microbiota in Parkinson's disease patients/healthy spouses and its association with clinical features	61
Gut microbiome in Parkinson's disease: New insights from meta-analysis	60
Unmet needs in Parkinson disease: Motor and non-motor	58
Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study	52
Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression	47
Rapid worsening in Parkinson's disease may hide COVID-19 infection	46
The changes of exercise pattern and clinical symptoms in patients with Parkinson's disease in the era of COVID-19 pandemic	45
Serum neurofilament light chain levels reflect cortical neurodegeneration in de novo Parkinson's disease	43
COVID-19 in Parkinson's disease: Report on prevalence and outcome	43
Machine learning-assisted neurotoxicity prediction in human midbrain organoids	41
Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO study	40
Clinical implications of gastric complications on levodopa treatment in Parkinson's disease	39
The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension	39
Cerebral small vessel disease may worsen motor function, cognition, and mood in Parkinson's disease	38
Exosomal miRNA as peripheral biomarkers in Parkinson's disease and progressive supranuclear palsy: A pilot study	37
Serum NFL levels predict progression of motor impairment and reduction in putamen dopamine transporter binding ratios in de novo Parkinson's disease: An 8-year longitudinal study	35
Increased diagnostic yield in complex dystonia through exome sequencing	34
How do adenosine A2A receptors regulate motor function?	33
Early cognitive decline after bilateral subthalamic deep brain stimulation in Parkinson's disease patients with GBA mutations	32
Hierarchical cluster analysis of multimodal imaging data identifies brain atrophy and cognitive patterns in Parkinson’s disease	32

Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis	31
Tau and MAPT genetics in tauopathies and synucleinopathies	30
The challenge of developing adenosine A2A antagonists for Parkinson disease: Istradefylline, preladenant, and tozadenant	30
Prolonged-release melatonin in Parkinson's disease patients with a poor sleep quality: A randomized trial	30
The use of wearable/portable digital sensors in Huntington's disease: A systematic review	29
Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review	29
A physical therapy programme for functional motor symptoms: A telemedicine pilot study	29
Telemedicine for parkinsonism: A two-step model based on the COVID-19 experience in Milan, Italy	29
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial	28
Predicting Parkinson's disease using gradient boosting decision tree models with electroencephalography signals	28
Effects of cerebellar transcranial magnetic stimulation on ataxias: A randomized trial	28
Life expectancy of parkinsonism patients in the general population	28
Diagnostic accuracy of the appearance of Nigrosome-1 on magnetic resonance imaging in Parkinson's disease: A systematic review and meta-analysis	28
Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: A population-based cohort study	28
ND0612 (levodopa/carbidopa for subcutaneous infusion) in patients with Parkinson's disease and motor response fluctuations: A randomized, placebo-controlled phase 2 study	27
Features of “ET plus” correlate with age and tremor duration: “ET plus” may be a disease stage rather than a subtype of essential tremor	27
Plasma NfL, clinical subtypes and motor progression in Parkinson's disease	27
Parkinson's disease and skin	27
Utility of quantitative EEG in early Lewy body disease	27
High-frequency repetitive transcranial magnetic stimulation over the primary motor cortex relieves musculoskeletal pain in patients with Parkinson's disease: A randomized controlled trial	27
Impact of home confinement during COVID-19 pandemic on Parkinson's disease	27
Progressive and accelerated weight and body fat loss in Parkinson's disease: A three-year prospective longitudinal study	27
Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder – A PET study	26
Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?	26
Ambroxol increases glucocerebrosidase (GCase) activity and restores GCase translocation in primary patient-derived macrophages in Gaucher disease and Parkinsonism	26
The late stage of Parkinson's –results of a large multinational study on motor and non-motor complications	26
Moving towards home-based community-centred integrated care in Parkinson's disease	26
Rate of progression from mild cognitive impairment to dementia in an essential tremor cohort: A prospective, longitudinal study	26
Probiotics for constipation and gut microbiota in Parkinson's disease	25
Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance	25
Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis	25
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications	25
Use of machine learning method on automatic classification of motor subtype of Parkinson's disease based on multilevel indices of rs-fMRI	24
Dysphagia in multiple system atrophy consensus statement on diagnosis, prognosis and treatment	24
Progressive loss of raphe nuclei serotonin transporter in early Parkinson's disease: A longitudinal 123I-FP-CIT SPECT study	24
Diagnostic value of α-synuclein seeding amplification assays in α-synucleinopathies: A systematic review and meta-analysis	23
Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic	23
Closed-loop programming using external responses for deep brain stimulation in Parkinson's disease	23
Prevalence of ten LRRK2 variants in Parkinson's disease: A comprehensive review	23
Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson's disease?	22
Art therapy for Parkinson's disease	22
Comparison of 123I-MIBG scintigraphy and phosphorylated α-synuclein skin deposits in synucleinopathies	22
Prediagnostic motor and non-motor symptoms in progressive supranuclear palsy: The step-back PSP study	22
A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson's disease. The ERCOPARK study	22
The psychological impact of COVID-19 among a sample of Italian patients with functional neurological disorders: A preliminary study	22
Plasma immune markers in an idiopathic REM sleep behavior disorder cohort	22
Long-term effect of bilateral STN-DBS on non-motor symptoms in Parkinson's disease: A four-year observational, prospective study	21
E-Rehabilitation: One solution for patients with Parkinson's disease in COVID-19 era	21
Prevalence and clinical associations of tau in Lewy body dementias: A systematic review and meta-analysis	21
The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques	21

Peripheral insulin and amylin levels in Parkinson's disease	21
The evolution of parkinsonism in primary progressive apraxia of speech: A 6-year longitudinal study	20
Diagnostic criteria for blepharospasm: A multicenter international study	20
Subjective cognitive Complaints in early Parkinson's disease patients with normal cognition are associated with affective symptoms	20
Movement disorders induced by psychiatric drugs that do not block dopamine receptors	20
Novel and reported variants in Parkinson's disease genes confer high disease burden among Indians	20
Cognitive impairment in Parkinson's disease is associated with Default Mode Network subsystem connectivity and cerebrospinal fluid Aβ	20
Plasma neurofilament light in Huntington's disease: A marker for disease onset, but not symptom progression	20
Are there morphological differences between Parkinson's disease-dementia and dementia with Lewy bodies?	20
The diagnostic value of clinical neurophysiology in hyperkinetic movement disorders: A systematic review	19
Serum neurofilament is associated with motor function, cognitive decline and subclinical cardiac damage in advanced Parkinson's disease (MARK-PD)	19
The presence of a caregiver is associated with patient outcomes in patients with Parkinson's disease and atypical parkinsonisms	19
Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers	19
The inconsistency and instability of Parkinson's disease motor subtypes	19
Oropharyngeal freezing and its relation to dysphagia – An analogy to freezing of gait	18
Social cognitive impairment in early Parkinson's disease: A novel “mild impairment”?	18
Telemedicine and Deep brain stimulation - Current practices and recommendations	18
Parkinson's disease motor subtype changes during 20 years of follow-up	18
Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis	18
Trends of inpatient palliative care use among hospitalized patients with Parkinson's disease	18
Geospatial analysis of individual-based Parkinson's disease data supports a link with air pollution: A case-control study	18
Digital phenotyping in Parkinson's disease: Empowering neurologists for measurement-based care	18
Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: A systematic review and Bayesian network meta-analysis	18
The commercial genetic testing landscape for Parkinson's disease	17
Anxiety in Parkinson's disease is associated with changes in the brain fear circuit	17
A pilot to assess target engagement of terazosin in Parkinson's disease	17
Functional movement disorder comorbidity in Parkinson's disease: Unraveling the web	17
Ischemic injury precipitates neuronal vulnerability in Parkinson's disease: Insights from PINK1 mouse model study and clinical retrospective data	16
Consistent skin α-synuclein positivity in REM sleep behavior disorder – A two center two-to-four-year follow-up study	16
Multidisciplinary inpatient rehabilitation for Functional Movement Disorders: A prospective study with long term follow up	16
Association of PSP phenotypes with survival: A brain-bank study	16
A trial of buspirone for anxiety in Parkinson's disease: Safety and tolerability	16
Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease	16
Classification and staging of Parkinson's disease using video-based eye tracking	16
Perivascular space in Parkinson's disease: Association with CSF amyloid/tau and cognitive decline	16
Automated assessment of the substantia nigra on susceptibility map-weighted imaging using deep convolutional neural networks for diagnosis of Idiopathic Parkinson's disease	16
Relating Parkinson freezing and balance domains: A structural equation modeling approach	16
SLC25A46 mutations in patients with Parkinson's Disease and optic atrophy	16
Quantitative assessment of posture in healthy controls and patients with Parkinson's disease	16
Prefrontal network dysfunctions in rapid eye movement sleep behavior disorder	16
Impaired metabolic brain networks associated with neurotransmission systems in the α-synuclein spectrum	16
Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?	16
Cerebello-basal ganglia connectivity fingerprints related to motor/cognitive performance in Parkinson's disease	16
Dual-task clinical and functional MRI correlates in Parkinson's disease with postural instability and gait disorders	15
WARS2 mutations cause dopa-responsive early-onset parkinsonism and progressive myoclonus ataxia	15
Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients	15
Parkinsonism in children: Clinical classification and etiological spectrum	15
Necessity and feasibility of remote tele-programming of deep brain stimulation systems in Parkinson's disease	15
Combined CSF α-SYN RT-QuIC, CSF NFL and midbrain-pons planimetry in degenerative parkinsonisms: From bedside to bench, and back again	15
Bilateral pallidal stimulation improves cervical dystonia for more than a decade	15
FIG4 mutations leading to parkinsonism and a phenotypical continuum between CMT4J and Yunis Varón syndrome	15
Normal cognition in Parkinson's disease may involve hippocampal cholinergic compensation: An exploratory PET imaging study with [18F]-FEOBV	15
Should we start integrating genetic data in decision-making on device-aided therapies in Parkinson disease? A point of view	15
IRF2BPL mutation causes nigrostriatal degeneration presenting with dystonia, spasticity and keratoconus	15
Low-frequency oscillation suppression in dystonia: Implications for adaptive deep brain stimulation	15
In vivo cholinergic basal forebrain degeneration and cognition in Parkinson's disease: Imaging results from the COPPADIS study	15
Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism	15
Can AI make people happy? The effect of AI-based chatbot on smile and speech in Parkinson's disease	15
Mind the gap: Inequalities in mental health care and lack of social support in Parkinson disease	15
Scientific impact of movement disorders research from Southeast Asia: A bibliometric analysis	15
A validated measure of rigidity in Parkinson's disease using alternating finger tapping on an engineered keyboard	15
Clinically relevant copy-number variants in exome sequencing data of patients with dystonia	15
Neuropathological findings in PINK1-associated Parkinson's disease	15
Parkinson's disease motor subtypes and bilateral GPi deep brain stimulation: One-year outcomes	14
Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder	14
Apolipoprotein E ε4 genotype and risk of freezing of gait in Parkinson's disease	14
A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson's disease	14
Sex differences in dementia with Lewy bodies: Focused review of available evidence and future directions	14
Effect of deep brain stimulation on caregivers of patients with Parkinson's disease: A systematic review	14
Voice characteristics from isolated rapid eye movement sleep behavior disorder to early Parkinson's disease	14
A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi – A long term follow-up after up to 15 years	14
Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank	14
Clinical-Instrumental patterns of neurodegeneration in Essential Tremor: A data-driven approach	14
PINK1 p.Leu347Pro mutations in Malays: Prevalence and illustrative cases	13
Cerebrospinal fluid and plasma distribution of anti-α-synuclein IgMs and IgGs in multiple system atrophy and Parkinson's disease	13
Determining an efficient deep brain stimulation target in essential tremor - Cohort study and review of the literature	13
Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study	13
Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders	13
Clinical patterns of gait freezing in Parkinson's disease and their response to interventions: An observer-blinded study	13
Machine learning trained with quantitative susceptibility mapping to detect mild cognitive impairment in Parkinson's disease	13

GBA variation and susceptibility to multiple system atrophy	13
Exploring the clinical meaningfulness of the Scale for the Assessment and Rating of Ataxia: A comparison of patient and physician perspectives at the item level	13
Neurogenic orthostatic hypotension in early stage Parkinson's disease: New insights from the first 105 patients of the BoProPark study	13
Multimodal assessment of nigrosomal degeneration in Parkinson's disease	13
A novel mutation in PSEN1 (p.Arg41Ser) in an Argentinian woman with early onset Parkinsonism	13
Motor and non-motor subtypes of cervical dystonia	13
Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria	13
Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease	13
Risk of Parkinson's disease in patients with hypothyroidism: A nationwide population-based cohort study	13
Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis	13
Quantitative mobility measures complement the MDS-UPDRS for characterization of Parkinson's disease heterogeneity	13
Isolated parkinsonism is an atypical presentation of GRN and C9orf72 gene mutations	13
Validation of a UPDRS-/MDS-UPDRS-based definition of functional dependency for Parkinson's disease	13
Female, aging, difference formulations of DCI, or lower body weight increases AUC4hr of levodopa in patients with Parkinson's disease	13
Cortical microstructural correlates of plasma neurofilament light chain in Huntington's disease	12
Effect of eight-week online cognitive training in Parkinson's disease: A double-blind, randomized, controlled trial	12
A new alpha-synuclein missense variant (Thr72Met) in two Turkish families with Parkinson's disease	12
Patterns and predictors of referrals to allied health services for individuals with Parkinson's disease: A Parkinson's foundation (PF) QII study	12
Clinical manifestations of Parkinson's disease harboring VPS35 retromer complex component p.D620N with long-term follow-up	12
Basal ganglia and cerebellar circuits have distinct roles in blepharospasm	12
Toll-like receptor 4 deficiency facilitates α-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson's disease	12
The cerebellum in idiopathic cervical dystonia: A specific pattern of structural abnormalities?	12
Increased prevalence of Parkinson's disease in soils with high arsenic levels	12
High intensity aerobic exercise improves bimanual coordination of grasping forces in Parkinson's disease	12
White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease	12
Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum	12
Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany	12
Predicting Parkinson's disease trajectory using clinical and neuroimaging baseline measures	12
Cerebrospinal fluid biomarker profiling in corticobasal degeneration: Application of the AT(N) and other classification systems	12
Clinical perception and management of Parkinson's disease during the COVID-19 pandemic: A Canadian experience	12
Constipation distinguishes different clinical-biochemical patterns in de novo Parkinson's disease	12
Impulsive and compulsive behaviors in Parkinson's disease: Impact on quality of and satisfaction with life, and caregiver burden	12
The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease	12
BDNF levels and nigrostriatal degeneration in “drug naïve” Parkinson's disease patients. An “in vivo” study using I-123-FP-CIT SPECT	12
The neurological and neuropsychiatric spectrum of adults with late-treated phenylketonuria	12
Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and “OFF” episodes	12
Clarification of undiagnosed ataxia using whole-exome sequencing with clinical implications	12
Predictors of general and health-related quality of life in Parkinson's disease and related disorders including caregiver perspectives	12
Biofluid markers of blood-brain barrier disruption and neurodegeneration in Lewy body spectrum diseases: A systematic review and meta-analysis	12
Drooling rating scales in Parkinson's disease: A systematic review	12
Fatigue in hypokinetic, hyperkinetic, and functional movement disorders	12
Relationship between risk and protective factors and clinical features of Parkinson's disease	12
The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation	12
No enhanced (p-) α-synuclein deposition in gastrointestinal tissue of Parkinson's disease patients	12
Longitudinal evaluation of patients with isolated head tremor	11
Initial center of pressure position prior to anticipatory postural adjustments during gait initiation in people with Parkinson's disease with freezing of gait	11
Ataxia and tolerance after thalamic deep brain stimulation for essential tremor	11
Association of lipid levels with motor and cognitive function and decline in advanced Parkinson's disease in the Mark-PD study	11
A wearable tool for selective and continuous monitoring of tremor and dyskinesia in Parkinsonian patients	11
Beyond 10 years of levodopa intestinal infusion experience: Analysis of mortality and its predictors	11
Rest tremor correlates with reduced contralateral striatal dopamine transporter binding in Parkinson's disease	11
Paired inhibitory stimulation and gait training modulates supplemental motor area connectivity in freezing of gait	11
Altered gut microbiota in Parkinson's disease patients with motor complications	11
α and θ oscillations in the subthalamic nucleus are potential biomarkers for Parkinson's disease with depressive symptoms	11
Natural speech markers of Alzheimer's disease co-pathology in Lewy body dementias	11
Neuroimaging outcomes associated with mild cognitive impairment subtypes in Parkinson's disease: A systematic review	11
The faecal metabolome and mycobiome in Parkinson's disease	11
Objective measurement of limb bradykinesia using a marker-less tracking algorithm with 2D-video in PD patients	11
Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease	11
Neuromelanin-sensitive magnetic resonance imaging in disease differentiation for parkinsonism or neurodegenerative disease affecting the basal ganglia	11
Diffusion imaging in dementia with Lewy bodies: Associations with amyloid burden, atrophy, vascular factors and clinical features	11
Multimodal dopamine transporter (DAT) imaging and magnetic resonance imaging (MRI) to characterise early Parkinson's disease	11
Spinocerebellar ataxias in Asia: Prevalence, phenotypes and management	11
Efficacy results of pimavanserin from a multi-center, open-label extension study in Parkinson's disease psychosis patients	11
Exome-wide rare variant analysis in familial essential tremor	11
Predictors of fatigue severity in early, de novo Parkinson disease patients: A 1-year longitudinal study	11
Motor outcomes and adverse effects of deep brain stimulation for dystonic tremor: A systematic review	11
Parkinson's disease polygenic risk score is not associated with impulse control disorders: A longitudinal study	11
The amplitude of low-frequency fluctuation predicts levodopa treatment response in patients with Parkinson's disease	11
Soluble LAG-3 and Toll-interacting protein: Novel upstream neuro-inflammatory markers in Parkinson's disease	11
Mutation screening of VPS16 gene in patients with isolated dystonia	11
Dentate nucleus stimulation for essential tremor	11
Patterns of diffusion kurtosis changes in Parkinson's disease subtypes	11
α-Synuclein seed amplification assay as a diagnostic tool for parkinsonian disorders	11
Expanding sexual and gender minority research in movement disorders: More than awareness and acceptance	11
Correlations between retinal nerve fiber layer thickness and cognitive progression in Parkinson's disease: A longitudinal study	11
Homozygosity mapping and next generation sequencing for the genetic diagnosis of hereditary ataxia and spastic paraplegia in consanguineous families	10
Beta power and movement-related beta modulation as hallmarks of energy for plasticity induction: Implications for Parkinson's disease	10
Extrastriatal 123I-FP-CIT SPECT impairment in degenerative parkinsonisms	10
Clinical phenotypes, genotypes and treatment in Chinese dystonia patients with KMT2B variants	10
Cognitive impairment in spinocerebellar ataxia type 12	10
Association between probable REM sleep behavior disorder and increased dermal alpha-synuclein deposition in Parkinson's disease	10
Lesions of the cerebello-thalamic tract rather than the ventral intermediate nucleus determine the outcome of focused ultrasound therapy in essential tremor: A 3T and 7T MRI–study	10
Progressive microstructural alterations in subcortical nuclei in Parkinson's disease: A diffusion magnetic resonance imaging study	10
Movement disorders in systemic autoimmune diseases: Clinical spectrum, ancillary investigations, pathophysiological considerations	10
Paroxysmal movement disorder with response to carbamazepine in a patient with RHOBTB2 developmental and epileptic encephalopathy	10
Electroretinography reveals retinal dysfunction in Parkinson's disease despite normal high-resolution optical coherence tomography findings	10
The association of comorbidity with Parkinson's disease-related hospitalizations	10
The global pandemic has permanently changed the state of practice for pre-DBS neuropsychological evaluations	10
Subcortical microstructural diffusion changes correlate with gait impairment in Parkinson's disease	10
Pre-diagnostic presentations of Multiple System Atrophy case control study in a primary care dataset	10
Hippocampal and insula volume in mild cognitive impairment with Lewy bodies	10
Autosomal dominant GCH1 mutations causing spastic paraplegia at disease onset	10
Arterial spin labeling detects perfusion patterns related to motor symptoms in Parkinson's disease	10
Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study	10